Complejo Hospitalario Universitario Insular Materno Infantil — Clinical Trial Site

132 Registered trials

59 Currently recruiting

Organisation

Complejo Hospitalario Universitario Insular Materno Infantil

Location

Las Palmas De Gran Canaria, Spain

Identifier

ORG-100043600

Address

Autovia Del Sur S/n, 35017, Spain

Departments

#034007 Oncologia
#3444: Endocrinología
#5708: Oncology
Alergology
Allergology
Cardiology
Endocrinologia
Haematology
Hematología
Hematology and Hemotherapy
Hematology Department
Inherited Cardiac Diseases Unit, Cardiology department
Internal medicine- Infectious Disease Department
Medical Oncology
Medical Oncology Department
n/a
Oftalmología
Oncolgy
Oncología
Oncología Médica
Oncology
Oncology Department
Oncology Medicine
Oncology service
Ophthalmology
Pediatric
Pediatric oncology
Pediatric oncology department
Servicio de digestivo
Servicio de Endocrinología y Nutrición
Servicio de Oncologia
Servicio de Oncología médica
Surgery
Urology

Clinical trials at this site (132)

Search interface

A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients with Operable No… Recruiting

2023-509806-31-00 Non-Small Cell Lung Cancer 4 2025-02-11
MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting

2023-507776-42-00 Non-small cell lung cancer 5 2024-11-14
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
HARMONi-3 Recruiting

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Unresectable and/or Metastatic HER2-low or HER2 Immunoh 4 2024-09-04
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced … Recruiting

2024-517363-24-00 Advanced FIGO Stage III‐IV High Grade Serous or Endomet 4 2024-02-16
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting

2023-504999-25-00 Acute Myeloid Leukemia 5 2023-07-14
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting

2022-500967-11-00 Previously Untreated Metastatic or Unresectable Melanom 5 2023-07-06
A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o… Recruiting

2024-516331-27-00 Participants with BRAF and/or NRAS mutation positive tu 3 2022-06-10
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects wi… Recruiting

2024-514010-12-00 Advanced Malignancies 1 2020-12-03
LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting

2023-508101-24-00 Lymphoblastic lymphoma 5 2019-08-01
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years Recruiting

2024-518254-16-00 Acute Myeloid Leukemia (Pediatric 0-18 years) 5 2013-03-01
MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Ended

2023-503539-16-00 Non-small Cell Lung Cancer (NSCLC) 5 2025-11-11
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended

2024-516051-40-00 Small Cell Lung Cancer (SCLC) 4 2025-06-10
Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/D… Ended

2024-518519-20-01 moderate/severe allergic rhinitis/rhinoconjunctivitis w 4 2025-04-10
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line t… Ended

2024-514728-17-00 Advanced or recurrent endometrial cancer 11 2024-12-30